CDIO
Cardio Diagnostics Holdings, Inc.NASDAQHealthcare$2.04+0.00%ClosedMarket Cap: $3.8M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.52
P/S
247.50
EV/EBITDA
0.12
DCF Value
$2.32
FCF Yield
-162.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2180.2%
Operating Margin
-43737.5%
Net Margin
-43832.5%
ROE
-71.7%
ROA
-83.7%
ROIC
-84.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.6K | $-1.5M | $-0.80 |
| FY 2025 | $14.8K | $-6.5M | $-3.71 |
| Q3 2025 | $2.9K | $-1.7M | $-0.98 |
| Q2 2025 | $7.5K | $-1.7M | $-0.97 |
Trading Activity
Insider Trades
View AllBurton Paul Frederickdirector
SellThu Apr 02
Intrater Jamesdirector
SellThu Apr 02
Betts Wendy Jdirector
SellThu Apr 02
Fung Peter Kdirector
SellThu Apr 02
Fung Peter Kdirector
SellTue Jan 06
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.66
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.